John B. Warren
Research Subjects
John B. Warren has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Hans G. Stampfer
University of Western Australia, Perth, WA
2 shared publications - Simon B. Dimmitt
School of Medicine and Pharmacology, University of Western Australia, Subiaco, WA 6008, Australia
2 shared publications Hans G. Stampfer
School of Psychiatry and Clinical Neurosciences, Level 1, D Block, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, 6009
1 shared publicationKersti Oselin
Medicines and Healthcare Products Regulatory Agency, 151 Buckingham Palace Road, London SW1W 9SZ, UK
1 shared publication- Michael James Paech
Department of Anaesthesia and Pain Medicine, King Edward Memorial Hospital for Women, Perth, Western Australia, Australia
1 shared publication Simon B. Dimmitt
School of Medicine and Pharmacology, University of Western Australia, Subiaco, Western Australia, 6008
1 shared publication
Latest Publications
- Open Access
- 1 November 2018
- Published by Elsevier in The Lancet Psychiatry
- Vol. 5 (11) , 871
Unbalanced risk-benefit analysis of ADHD drugs
- 1 November 2018
- Published by Elsevier in The Lancet Psychiatry
- Vol. 5 (11) , 871
Open AccessUnbalanced risk-benefit analysis of ADHD drugs
- Open Access
- 1 September 2018
- Published by Elsevier in The Lancet
- Vol. 392 (10152) , 1010-1011
Network meta-analysis of antidepressants
- 1 September 2018
- Published by Elsevier in The Lancet
- Vol. 392 (10152) , 1010-1011
Open AccessNetwork meta-analysis of antidepressants
- 28 November 2016
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 83 (2) , 221-223
Composite endpoints and the distortion of risk–benefit analysis
- 28 November 2016
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 83 (2) , 221-223
Composite endpoints and the distortion of risk–benefit analysis
- 2 May 2016
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 82 (1) , 168-177
Cholesterol trials and mortality
An overview of clinical trials can reveal a class effect on mortality that is not apparent from individual trials. Most large trials of lipid pharmacotherapy are not powered to detect differences in mortality and instead assess efficacy with composite cardiovascular endpoints. We illustrate the importance of all‐cause mortality data by comparing survival in three different sets of the larger controlled lipid trials that underpin meta‐analyses. These trials are for fibrates and statins. Fibrate treatment in five of the six main trials was associated with a decrease in survival, one fibrate trial showed a non‐significant reduction in mortality that can be explained by a different target population. In secondary prevention, statin treatment increased survival in all five of the main trials, absolute mean increase ranged from 0.43% to 3.33%, the median change was 1.75%, which occurred in the largest trial. In primary prevention, statin treatment increased survival in six of the seven main trials, absolute mean change in survival ranged from −0.09% to 0.89%, median 0.49%. Composite safety endpoints are rare in these trials. The failure to address composite safety endpoints in most lipid trials precludes a balanced summary of risk–benefit when a composite has been used for efficacy. Class effects on survival provide informative summaries of the risk–benefit of lipid pharmacotherapy. We consider that the presentation of key mortality/survival data adds to existing meta‐analyses to aid personal treatment decisions.
- 2 May 2016
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 82 (1) , 168-177
Cholesterol trials and mortality
An overview of clinical trials can reveal a class effect on mortality that is not apparent from individual trials. Most large trials of lipid pharmacotherapy are not powered to detect differences in mortality and instead assess efficacy with composite cardiovascular endpoints. We illustrate the importance of all‐cause mortality data by comparing survival in three different sets of the larger controlled lipid trials that underpin meta‐analyses. These trials are for fibrates and statins. Fibrate treatment in five of the six main trials was associated with a decrease in survival, one fibrate trial showed a non‐significant reduction in mortality that can be explained by a different target population. In secondary prevention, statin treatment increased survival in all five of the main trials, absolute mean increase ranged from 0.43% to 3.33%, the median change was 1.75%, which occurred in the largest trial. In primary prevention, statin treatment increased survival in six of the seven main trials, absolute mean change in survival ranged from −0.09% to 0.89%, median 0.49%. Composite safety endpoints are rare in these trials. The failure to address composite safety endpoints in most lipid trials precludes a balanced summary of risk–benefit when a composite has been used for efficacy. Class effects on survival provide informative summaries of the risk–benefit of lipid pharmacotherapy. We consider that the presentation of key mortality/survival data adds to existing meta‐analyses to aid personal treatment decisions.
- 9 June 2015
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 115 (eLetters)
Hazards of perioperative beta blockers likely dose related
- 9 June 2015
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 115 (eLetters)
Hazards of perioperative beta blockers likely dose related
- 1 June 2015
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 80 (1) , 170-171
Common statin side effects explain poor compliance
- 1 June 2015
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 80 (1) , 170-171
Common statin side effects explain poor compliance
- 8 December 2011
- Published by Wiley
- Vol. 73 (1) , 146
Drug Safety Evaluation
- 11 October 2011
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 72 (5) , 733-734
Comment on: Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe by Johnston et al.[1]
- 11 October 2011
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 72 (5) , 733-734
Comment on: Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe by Johnston et al.[1]
- Open Access
- 10 November 2010
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 71 (4) , 497-503
Drug discovery: lessons from evolution
A common view within the pharmaceutical industry is that there is a problem with drug discovery and we should do something about it. There is much sympathy for this from academics, regulators and politicians. In this article I propose that lessons learnt from evolution help identify those factors that favour successful drug discovery. This personal view is influenced by a decade spent reviewing drug development programmes submitted for European regulatory approval. During the prolonged gestation of a new medicine few candidate molecules survive. This process of elimination of many variants and the survival of so few has much in common with evolution, an analogy that encourages discussion of the forces that favour, and those that hinder, successful drug discovery. Imagining a world without vaccines, anaesthetics, contraception and anti-infectives reveals how medicines revolutionized humanity. How to manipulate conditions that favour such discoveries is worth consideration.
- 10 November 2010
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 71 (4) , 497-503
Open AccessDrug discovery: lessons from evolution
A common view within the pharmaceutical industry is that there is a problem with drug discovery and we should do something about it. There is much sympathy for this from academics, regulators and politicians. In this article I propose that lessons learnt from evolution help identify those factors that favour successful drug discovery. This personal view is influenced by a decade spent reviewing drug development programmes submitted for European regulatory approval. During the prolonged gestation of a new medicine few candidate molecules survive. This process of elimination of many variants and the survival of so few has much in common with evolution, an analogy that encourages discussion of the forces that favour, and those that hinder, successful drug discovery. Imagining a world without vaccines, anaesthetics, contraception and anti-infectives reveals how medicines revolutionized humanity. How to manipulate conditions that favour such discoveries is worth consideration.